Blonanserin: AD 5423

Source: Drugs in R&D, Volume 3, Number 6, 2002 , pp. 405-406(2)

Buy & download fulltext article:

Price: $57.95 plus tax (Refund Policy)

Abstract:

Adis Comments

Blonanserin [AD 5423] is a combined dopamine D and serotonin receptor antagonist, currently undergoing development in Japan with Dainippon Pharmaceutical as a potential antipsychotic agent.Blonanserin is unrelated structurally to typical antipsychotics or to newer agents such as risperidone. It is hoped that the combination of receptor blockade possessed by blonanserin will be effective against both the positive and negative symptoms of schizophrenia, with a low tendency to cause extrapyramidal symptoms. Blonanserin is expected to have minimal sedative and hypotensive effects, as its adrenaline alpha -receptor blocking function is weak.

Dainippon is conducting phase III clinical trials with oral formulations (tablet and powder) of the compound in psychotic disorders. In August 2002, Dainippon stated that it was preparing an application to file for approval in Japan.

In May 2001, Dainippon announced that it had licensed exclusive marketing and development rights for blonanserin to Almirall Prodesfarma for all countries other than Japan, China, Taiwan and South Korea. Almirall is conducting phase I trials in Europe investigating the use of blonanserin as an antipsychotic agent.

Keywords: Adis R and D Profiles; Blonanserin, general; Dopamine D2 receptor antagonists, general; Research and development; Serotonin 2 receptor antagonists, general

Language: English

Document Type: Miscellaneous

Publication date: 2002-01-01